Эффективность Таксотера в неоадъювантной и адъювантной химиотерапии рака молочной железы

1. Борисов В.И. Комбинированные и последовательные режимы назначения Таксотера с антрациклинами в адъювантной терапии РМЖ. Возможности улучшения безрецидивной выживаемости. Материалы конференции. «Белые ночи». Санкт-Петербург, 2008.
2. Горбунова В.А., Бесова Н.С. Значение таксанов в лечении рака молочной железы. Вопросы онкологии, 2004; 50 (4).
3. Моисеенко В.М., Семиглазов В.Ф., Тюляндин С.А. Современное лекарственное лечение местно-распространенного и метастатического рака молочной железы. Санкт-Петербург: Грифон 1997; 254.
4. Семиглазов В.Ф. Неоадъювантная химиотерапия РМЖ. Материалы конференции «Белые ночи». Санкт-Петербург, 2008.
5. Семиглазов В.Ф. Перспективы лечения пациентов с Erb2 (Her2)-позитивным раком молочной железы: Клинические исследования. Материалы конференции «Белые ночи». Санкт-Петербург, 2008.
6. Стенина М.Б. Таксотер в адъювантной терапии рака молочной железы. Издательский дом «Русский врач», Врач, 2008; (5) 4.
7. Стенина М.Б. Безантрациклиновые режимы в адъювантной химиотерапии РМЖ. Материалы конференции «Белые ночи» Санкт-Петербург, 2008.
8. Baltali E, Ozisik Y., Guler N. et al. Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer Tumori. 2001; 87: 18–9.
9. Bear H D., Anderson S et al. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 2003; 21: 4165–74. 
10. Bear H D., Anderson S et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 2006; 24: 2019–27.
11. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer N. Engl. J. Med. 1981; 304 (1): 10–5.
12. Bonneterre J, Dieras V, Tubiana-Hulin M et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004; 91: 1466–71.
13. Bontenbal M, Creemers G-J et al. Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre J Clin Oncol 2005; 23:7081–88.
14. Bums H, Perez E, Nabholtz J-M. Docetaxel / doxorubicin / cyclophosphamide versus 5-fluorouracil / doxorubicin / cyclophosphamide in the adjuvant setting (BCIRG 001): Understanding the Implications. Cancer Conference Highlights – Taxanes in the treatment of Operable Breast Cancer. Oct. 2002; 6 (12):7–8.
15. Chan S., Friedrichs K., Noel D. et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer // J. Clin. Oncol. 1999;17 (8): 2341–54.
16. Effects of chemotherapy and hormonal therapy for early breast cancer on recur¬rence and 15-year survival: an overview of the randomized trials Lancet. 2005; 365 (9472V. 1687–717.
17. Eiermann W., Pienkowski Т., Criwn J. et al. On behalf of the BCIRG 005 investi¬gators: Phase III randomised trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: interim analysis of the BCIRG 005 study Breast Canc. Res. Treat. – 2005; 94 (1): abstr. 1069.
18. Eiermann W, Pienkowski T et al. BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. SABCS 2008, abstract 77.
19. Estevez L.G., Munoz M., Alvarez I. et al. Evidence-based of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials Cancer treatment Reviews. 2007; 33: 474–83.
20. Evans J, Yellowlees A et al. Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study. J Clin Oncol 2005; 23: 2988–95.
21. Goldhrisch A., Wood W.C, Gelber R.D. et al. Progress and promise: highlights of the international experts consensus on the primary therapy of early breast cancer Ann. of Oncol. 2007; 18: 1133–44.
22. Heys S, Sarkar T., Hutcheon A. Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. Expert Opin Pharmacother 2004, 5(10): 2147–57.
23. Jones S.E., Savin M.A., Holmes F.A. et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J. Clin. Oncol. 2006; 24: 5381–87.
24. Jones S., Holmes F., O'Shaughnessy J. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older  SABCS. 2007, abstr 17.
25. Martin M et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvan docetaxel, doxo¬rubicin, cyclophosphamide (ТАС) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17:1205–12.
26. Martin M., Lluch A. et al. Effect of docetaxel-based adjuvant chemotherapy on disease-free survival in patients with high-risk node-negative breast cancer: Results from the GEICAM 9805 trial. ASCO 2008, abstr 154.
27. Martin M., Pienkovski Т., Mackey J. et al. Breast cancer international research group 001 investigators: Adjuvant docetaxel for node-positive breast cancer N. Engl. J. Med 2005; 352: 2302–13.
28. Minckwitz G., Raab G. et al. Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group J Clin Oncol 2005; 23: 2676–85.
29. Nabholtz J-M, Falkson C., Campos D. et al. Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial. J Clin Oncol 2003; 21 (6): 968–75.
30. Rastogi P, Anderson S et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol  2008; 26: 778–85.
31. Reitsamer R, Peintinger F. et al. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs, 2005 Sep; 16(8): 867–70.
32. Roche H., Fumoleau P., Spielmann M et al. Sequential adjuvant epirubicin- based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial J. Clin. Oncol. 2006; 24 (36): 5664–71.
33. Slamon D., Eiermann W. et al. Phase III randomized trial comparing doxorubi¬cin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclo¬phosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carbo-platin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG. 006 study.  SABCS. 2006; abstr 52.
34. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456–66.
35. Smith T. J., Khatcheressian J., Lyman G. et al. Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol. 2006; 24: 3187–05.
36. Steger G., Galid A. et al. Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14 J Clin Oncol 2007; 25: 2012–18.

Н.П. Макаренко, И.В.Поддубная

Кафедра онкологии ГОУ ДПО РМАПО, Москва